Abstract: A steering control device is provided with at least one of a first torque correction computing part and a second torque correction computing part; wherein the first torque correction computing part is equipped with a weight computing part which computes an increment of weight based on a magnitude of the driver torque, and accumulates the increment of weight to generate a weight, a clip value computing part which computes an automatic driver torque clip value according to the weight, and a clip processing part which clip processes the automatic driver torque with the automatic driver torque clip value; and the second torque correction computing part is equipped with a gain computing part which computes an increment of gain according to the driver torque, and accumulates the increment of gain to generate a gain, and a gain processing part which outputs an automatic driver torque multiplied by the gain.

Abstract: [Problem to be Solved] The present invention reduces usage of sodium chloride by adding magnesium chloride, and overcomes problems occurring in using magnesium chloride. [Solution] The present inventors have found that when magnesium chloride is added instead of sodium chloride to noodle strings and a reducing sugar is further added, preferable well-cooked feeling and appearance are imparted in subsequent production process for instant noodles, and thus, the present invention was accomplished. Specifically, the present invention relates to noodle strings for use in production of instant noodles, the noodle strings containing a raw material powder, magnesium chloride and a reducing sugar.

Abstract: Provided are a medium conveyance apparatus, control method, and control program to enable determining whether multi-feed of a medium has occurred by a greater precision. A medium conveyance apparatus includes a storage device to store in advance region information of a predetermined region in a medium, a feed roller to feed the medium, a slant detection module to detect an amount of slant of the fed medium, an overlap detection module to detect region information of a region in which overlap has occurred in the fed medium, a correction module to correct the detected region information based on the amount of slant, and a multi-feed determination module to determine that multi-feed of the medium has occurred if the corrected region information does not correspond to the stored region information and determine that multi-feed of the medium has not occurred if the corrected region information corresponds to the stored region information.

Abstract: A compound represented by formula (2) or pharmaceutically acceptable salt thereof: wherein R1 represents a hydrogen atom or the like; R2 represents a methoxy group or the like; R3 represents a hydrogen atom or the like; R4 represents an optionally substituted C1-6 alkyl group or the like; m represents 0, 1, or 2; n represents 0, 1, 2, or 3; L1 represents —NH—C(?O)—, —C(?O)—NH—, or the like; L2 represents a single bond or the like; X represents optionally substituted phenyl or the like; Y represents optionally substituted phenyl or the like; and X and Y are bonded at a carbon atom on each ring.

Abstract: The present invention relates to a medicament for treating various nervous system diseases or psychiatric diseases, comprising a compound of formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient, wherein R1 is hydrogen, etc., R2 is halogen, etc., R3, R4, R5, and R6 are hydrogen, etc.

Abstract: Provided herein are therapeutic and/or prophylactic compounds for mitochondrial or oxidative stress diseases such as cancer, amyotropic lateral sclerosis, Creutzfeldt-Jakob disease, Machado-Joseph disease, spinocerebellar ataxia, Huntington disease, Parkinson disease, Alzheimer disease, myocardial infarction, cerebral infarction, diseases related to aging, diabetes, alcoholic liver injury, chronic obstructive pulmonary disease, mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), and the like, wherein the compound is represented by formula (1), or reduced forms thereof, or pharmaceutically acceptable salts thereof.

Abstract: A medium conveying apparatus includes a floating sensor located on an upstream side of a first roller in the medium conveying direction to detect a floating of the medium placed on a medium tray, a skew sensor located on a downstream side of a second roller in the medium conveying direction to detect a skew of the medium conveyed by the second roller, and a processor to determine whether the floating of the medium has occurred based on an output signal from the floating sensor, determine whether the skew of the medium has occurred based on an output signal from the skew sensor, and determine that a conveyance abnormality of the medium has occurred when the processor determines that the floating of the medium has occurred and the processor determines that the skew of the medium has occurred.

Abstract: The present invention relates to a medicament for treating various nervous system diseases or psychiatric diseases, comprising a compound of formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient, wherein R1 is hydrogen, etc., R2 is halogen, etc., R3, R4, R5, and R6 are hydrogen, etc.

Abstract: The image reading apparatus includes a separation roller, an imaging device to generate an input image, a conveyance roller to convey the medium separated by the separation roller to the imaging device, a first medium sensor located between the separation roller and the conveyance roller, a second medium sensor located between the conveyance roller and the imaging device, a processor to start imaging by the imaging device in response to detection of the medium by the first medium sensor and generate a cutout image from the input image in response to detection of the medium by the second medium sensor, and an output device to output the cutout image. The processor generates the cutout image based on a position imaged by a predetermined amount before a position imaged at a timing when the second medium sensor detects the medium, in the input image.

Abstract: Provided is a 2-heteroaryl aminoquinazolinone derivative, which is a compound represented by formula (1): or a pharmaceutically acceptable salt thereof wherein X1 represents CR1 or N, X2 represents CR2 or N, X3 represents CR3 or N, X4 represents CR4 or N, Y represents optionally substituted C1-6 alkyl, an optionally substituted C3-10 alicyclic group, an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, optionally substituted C6-10 aryl, or optionally substituted 5- to 10-membered heteroaryl, Z represents optionally substituted 6- to 10-membered heteroaryl, and R1, R2, R3, and R4 each independently represent a hydrogen atom, halogen, cyano, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, or the like.

Abstract: A medium conveying apparatus includes a medium tray, a feed roller, an upper guide, a movement sensor including an arm movably provided by the fed medium on the upper guide and on an upstream side of the feed roller, to generate a movement amount signal corresponding to a movement amount of the arm, a medium sensor to detect a presence of the medium at a predetermined position of the medium tray, a processor to determine whether a feeding abnormality of the medium has occurred based on the movement amount signal, detect a size of the medium placed on the medium tray based on a detection result by the medium sensor, and stop feeding of the medium by the feed roller when the processor determines that the feeding abnormality of the media has occurred and the detected size of the media is equal to or less than a predetermined size.

Abstract: The present invention relates to a medicament for treating various nervous system diseases or psychiatric diseases, comprising a compound of formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient, wherein R1 is hydrogen, etc., R2 is halogen, etc., R3, R4, R5, and R6 are hydrogen, etc.

Abstract: A human-powered vehicle control device includes first and second rotary bodies, a transferring member that transfers drive force between the first and second rotary bodies, and a component. At least one of the first and second rotary bodies includes a plurality of rotary bodies. The component includes a transmission that performs a shifting action to move the transferring member between the plurality of rotary bodies. The control device includes an electronic controller controls the shifting action in accordance with a control condition set based on a travel state of the human-powered vehicle and/or a state of a rider. The electronic controller includes a first state that determines whether the control condition is satisfied and a second state that does not determine whether the control condition is satisfied. The electronic controller switches between the first and second states in accordance with a rotational state of the plurality of rotary bodies.

Abstract: A user interface of a bicycle derailleur is configured to receive a user input to execute at least one of: calibration in which a sensor is reset; changing an assist operation of an assist driving unit; changing information displayed in a display; a recovering operation by an actuator of the bicycle derailleur; a reset of a pairing operation; changing a shifting threshold used in an automatic shifting mode; changing a communication channel between a wired communication channel and a wireless communication channel; changing a function assigned to an operating device; a shut-down of a system of the bicycle derailleur; a wake-up operation of the system; a restart of the system; an operation of at least one additional bicycle component; changing a shifting mode between the automatic shifting mode and a manual shifting mode; and changing the shifting operation between a synchronized shifting mode and a non-synchronized shifting mode.

Abstract: Provided is a 2-heteroaryl aminoquinazolinone derivative, which is a compound represented by formula (1): or a pharmaceutically acceptable salt thereof wherein X1 represents CR1 or N, X2 represents CR2 or N, X3 represents CR3 or N, X4 represents CR4 or N, Y represents optionally substituted C1-6 alkyl, an optionally substituted C3-10 alicyclic group, an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, optionally substituted C6-10 aryl, or optionally substituted 5- to 10-membered heteroaryl, Z represents optionally substituted 6- to 10-membered heteroaryl, and R1, R2, R3, and R4 each independently represent a hydrogen atom, halogen, cyano, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, or the like.

Abstract: Provided herein are therapeutic and/or prophylactic compounds for mitochondrial or oxidative stress diseases such as cancer, amyotrophic lateral sclerosis, Creutzfeldt-Jakob disease, Machado-Joseph disease, spinocerebellar ataxia, Huntington disease, Parkinson disease, Alzheimer disease, myocardial infarction, cerebral infarction, diseases related to aging, diabetes, alcoholic liver injury, chronic obstructive pulmonary disease, mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), and the like, wherein the compound is represented by formula (1), or reduced forms thereof, or pharmaceutically acceptable salts thereof.

Abstract: The image reading apparatus includes a separation roller, an imaging device to generate an input image, a conveyance roller to convey the medium separated by the separation roller to the imaging device, a first medium sensor located between the separation roller and the conveyance roller, a second medium sensor located between the conveyance roller and the imaging device, a processor to start imaging by the imaging device in response to detection of the medium by the first medium sensor and generate a cutout image from the input image in response to detection of the medium by the second medium sensor, and an output device to output the cutout image. The processor generates the cutout image based on a position imaged by a predetermined amount before a position imaged at a timing when the second medium sensor detects the medium, in the input image.

Abstract: A medium conveying apparatus includes a processor to determine that a conveyance abnormality of a medium has occurred when a first medium sensor does not detect the medium when a motor is driven by a first predetermined amount after starting feeding of the medium, or when a second medium sensor does not detect the medium when the motor is driven by a second predetermined amount after the first medium sensor detects the medium, and calculate a degree of a slip occurred between the medium and a feed roller from when a front end of the medium passes through a position of the first medium sensor until the front end of the medium passes through a position of the second medium sensor. The processor changes the first predetermined amount or the second predetermined amount based on the degree of the slip of a medium fed in the past.

Abstract: The image reading apparatus includes a separation roller, an imaging device to generate an input image, a conveyance roller to convey the medium separated by the separation roller to the imaging device, a first medium sensor located between the separation roller and the conveyance roller, a second medium sensor located between the conveyance roller and the imaging device, a processor to start imaging by the imaging device in response to detection of the medium by the first medium sensor and generate a cutout image from the input image in response to detection of the medium by the second medium sensor, and an output device to output the cutout image. The processor generates the cutout image based on a position imaged by a predetermined amount before a position imaged at a timing when the second medium sensor detects the medium, in the input image.

Abstract: Provided is a 2-heteroaryl aminoquinazolinone derivative, which is a compound represented by formula (1): or a pharmaceutically acceptable salt thereof wherein X1 represents CR1 or N, X2 represents CR2 or N, X3 represents CR3 or N, X4 represents CR4 or N, Y represents optionally substituted C1-6 alkyl, an optionally substituted C3-10 alicyclic group, an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, optionally substituted C6-10 aryl, or optionally substituted 5- to 10-membered heteroaryl, Z represents optionally substituted 6- to 10-membered heteroaryl, and R1, R2, R3, and R4 each independently represent a hydrogen atom, halogen, cyano, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, or the like.